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Efficacy and Safety of Belimumab and Azathioprine for 
Maintenance of Remission in Antineutrophil Cytoplasmic 
Antibody–Associated Vasculitis: A Randomized Controlled 
Study
David Jayne,1 Daniel Blockmans,2  Raashid Luqmani,3 Sergey Moiseev,4 Beulah Ji,5 Yulia Green,5 Leanne Hall,6 
David Roth,7 Robert B. Henderson,6 and Peter A. Merkel8
Objective. To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain remission in anti-
neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).
Methods. In this multicenter, double- blind, placebo- controlled study, patients with AAV (ages ≥18 years) were 
randomized 1:1 to receive azathioprine (2 mg/kg/day), low- dose oral glucocorticoids (≤10 mg/day), and either intra-
venous belimumab (10 mg/kg) or placebo, following remission induction with rituximab or cyclophosphamide along 
with glucocorticoids. The primary end point was time to first protocol- specified event (PSE), with first PSE defined 
as a Birmingham Vasculitis Activity Score (BVAS) of ≥6, presence of ≥1 major BVAS item, or receipt of prohibited 
medications for any reason, resulting in treatment failure (adjusted for ANCA type [proteinase 3 (PR3) or myeloperox-
idase (MPO)], disease stage at induction, and induction regimen). Vasculitis relapse was defined as the PSE of either 
a BVAS activity score of ≥6 or receipt of prohibited medications for vasculitis. Changes in treatment practice led to 
truncation of the study population from ~300 patients to ~100 patients.
Results. The intent- to- treat population totaled 105 patients with AAV, of whom 52 (40 with PR3- ANCAs, 12 with 
MPO- ANCAs) received placebo and 53 (41 with PR3- ANCAs, 12 with MPO- ANCAs) received belimumab; 27 of the pa-
tients were in rituximab- induced disease remission, while 78 were in cyclophosphamide- induced disease remission at 
baseline. Compared with placebo, treatment with belimumab did not reduce the risk of a PSE (adjusted hazard ratio [HR] 
1.07, 95% confidence interval [95% CI] 0.44–2.59; P = 0.884) or vasculitis relapse (adjusted HR 0.88, 95% CI 0.29–2.65; 
P = 0.821). The overall rate of PSEs was low (11 [21.2%] of 52 patients receiving placebo, 10 [18.9%] of 53 patients 
receiving belimumab). Vasculitis relapse in the placebo group (n = 8) occurred independent of the induction regimen, 
disease stage, or ANCA type. All vasculitis relapses in the belimumab group (n = 6) occurred in patients who had PR3- 
ANCA–associated vasculitis with cyclophosphamide- induced disease remission. Adverse events occurred in 49 (92.5%) 
of 53 patients receiving belimumab and 43 (82.7%) of 52 patients receiving placebo, with no new safety concerns.
Conclusion. Belimumab plus azathioprine and glucocorticoids for the maintenance of remission in AAV did not 
reduce the risk of relapse.
INTRODUCTION
Granulomatosis with polyangiitis (GPA) and microscopic 
polyangiitis (MPA) (related types of antineutrophil cytoplasmic 
antibody [ANCA]–associated vasculitis [AAV]) are organ- and life- 
threatening systemic vasculitides characterized by the presence 
of autoantibodies. B cells have been implicated in the pathogen-
esis of AAV (1,2).
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The current recommendation for the maintenance of 
remission in AAV consists of treatment with low- dose glu-
cocorticoids in combination with one of the following thera-
pies: azathioprine, methotrexate, mycophenolate mofetil, or 
rituximab (3). Rituximab, a B cell–depleting agent shown to 
reduce the risk of relapse in GPA and MPA, is becoming the 
standard therapy for the induction of remission in AAV (4–8). 
Cyclophosphamide has similar efficacy as that of rituximab as 
an induction therapy (3,7). Despite use of the above therapies, 
relapse is a major clinical problem in AAV, and there remains 
uncertainty as to the best approach for preventing relapses 
after remission is obtained.
Several lines of evidence support a role for the B lym-
phocyte stimulator (BLyS) in the pathogenesis of AAV. BLyS 
is expressed by neutrophils, key cells in AAV pathogenesis, 
and elevated levels of circulating BLyS have been reported 
in patients with AAV (1,9–16). In addition, patients with 
systemic lupus erythematosus demonstrate increased lev-
els of BLyS following treatment with rituximab; such BLyS 
elevation may be linked to the production of autoantibod-
ies by autoreactive B cells (17–21). Belimumab, a human 
IgG1λ monoclonal antibody against BLyS, is licensed for the 
treatment of adults with active, autoantibody- associated 
systemic lupus erythematosus who are receiving standard 
therapy (22,23).
The current study, Belimumab in Remission of Vasculitis 
(BREVAS), examined the safety and efficacy of belimumab plus 
azathioprine and low- dose oral glucocorticoids for the mainte-
nance of remission in AAV, following induction of remission with 
either rituximab or cyclophosphamide with glucocorticoids. 
The treatments were tested within a randomized controlled trial 
 setting.
PATIENTS AND METHODS
Study design. In this multinational, multicenter, double- 
blind, placebo- controlled study (GlaxoSmithKline [GSK] study 
no. BEL115466; see Appendix A for a list of the collaborators) 
(23), patients with GPA or MPA were randomized 1:1 to receive 
treatment with either intravenous (IV) belimumab (10 mg/kg) or 
placebo alongside azathioprine (2 mg/kg/day) and low- dose oral 
glucocorticoids (≤10 mg/day) (Figure  1). The 37 participating 
centers were in 15 countries (in Australia, Central America, East-
ern Europe, North America, South America, and Western Europe). 
Randomization was performed on day 0; both the sites and study 
sponsor remained blinded with regard to treatment allocation at 
all times. The randomization schedule was produced by Human 
Genome Sciences (HGS).
Subjects were stratified by ANCA type (anti- PR3 ANCAs ver-
sus anti- MPO ANCAs), disease stage at induction (initial versus 
relapsing disease), and induction regimen (IV or oral cyclophos-
phamide versus rituximab). Subjects were assigned to their treat-
ment group via an Interactive Web Response System based on 
the parameters entered by the sites. When HGS was acquired by 
GSK, the randomization schedule was migrated to the GSK sys-
tem Randall. The first patient was enrolled on March 20, 2013 and 
the last patient visit took place on February 6, 2017. The study 
agent was administered on days 0, 14, 28, and every 28 days 
thereafter until either study completion or relapse.
The BREVAS study was originally a phase III study investi-
gating the maintenance or remission of AAV following a stan-
dard induction regimen. The study was truncated after initiation, 
primarily due to a change in AAV standard of care that affected 
recruitment. Furthermore, the study design changed from “event- 
driven” to “fixed completion” 12 months after the last patient was 
Figure 1. Study design. BVAS = Birmingham Vasculitis Activity Score; IV = intravenous; R = randomization; PSE = protocol- specified event.
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randomized, leading to variable durations of treatment. The sam-
ple size was reduced from ~300 patients to ~100 patients.
Institutional review board approval and ethics 
considerations. This study was reviewed and approved by 
the appropriate ethics committee or institutional review board in 
accordance with the International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for 
Human Use Guidelines for Good Clinical Practice, as well as the 
ethics procedures outlined in the Declaration of Helsinki (24) and 
applicable country- specific requirements. Written informed con-
sent was obtained from each patient prior to any study- specific 
procedures.
Patients. Inclusion criteria. Eligible patients were ages ≥18 
years, had a clinical diagnosis of GPA or MPA according to the 
2012 Chapel Hill Consensus Conference definitions (25), and 
tested positive (current or historical) for either PR3- ANCAs or 
MPO- ANCAs. Patients must have experienced either new- onset 
or relapsing GPA or MPA in the 26 weeks prior to day 0, that 
required treatment under one of the following remission induction 
regimens: a single course of rituximab (375 mg/m2/week for 4 
weeks) plus high- dose glucocorticoids; 2 doses of IV rituximab 
(1 gm), separated by a 2- week interval, plus high- dose gluco-
corticoids; oral cyclophosphamide (2 mg/kg/day); or pulses of IV 
cyclophosphamide (15 mg/kg), administered 2 weeks apart for 3 
doses followed by further pulses every 3 weeks, plus high- dose 
glucocorticoids. Additionally, patients had to be in remission on 
day 0 (with remission defined as a Birmingham Vasculitis Activity 
Score [BVAS; version 3] of 0) (26) and receiving glucocorticoids 
(presented as prednisone- equivalent doses) at ≤10 mg/day (on 
2 consecutive measurements ≥14 days apart, and 6–26 weeks 
after the first dose of induction therapy). Physicians were free to 
adjust the oral glucocorticoid dose in the range below 10 mg/day. 
A minimum period of 6 weeks was required between the first dose 
of induction therapy and randomization.
Exclusion criteria. Key exclusion criteria included the fol-
lowing: the coexistence of another autoimmune disease; any 
known intolerance or contraindications to azathioprine and 
methotrexate; receipt of any B cell–targeted therapy (exclud-
ing rituximab) at any time, or any other investigational agent 
within 60 days of day 0 or 5 half- lives of the agent (whichever 
was longest); any acute or chronic infections requiring hospi-
talization (within 60 days of day 0) and/or receipt of parenteral 
antibacterial drugs, antiviral drugs, antifungal drugs, or antipar-
asitic drugs (within 60 days of day 0); and serologic evidence of 
infection with human immunodeficiency virus, hepatitis B virus, 
or hepatitis C virus.
Efficacy end points and assessments. The primary 
objective of this study was to evaluate the efficacy and safety of 
belimumab in combination with azathioprine for the maintenance of 
remission in patients with GPA or MPA, following a standard remis-
sion induction regimen. Efficacy assessments and measurements 
of disease severity were performed according to the BVAS (version 
3) and Vasculitis Damage Index (VDI) scales (26,27). The primary 
end point was time to first protocol- specified event (PSE), with first 
PSE defined as a BVAS score of ≥6, presence of ≥1 predefined 
major item on the BVAS, or receipt of prohibited medications for any 
reason, resulting in treatment failure, as adjudicated by the sponsor. 
As treatment failure could occur for reasons other than vasculitis, 
a sensitivity analysis of vasculitis relapse was performed. Vasculitis 
relapses were defined as a BVAS score of ≥6, presence of a prede-
fined BVAS major item, or the receipt of prohibited medications for 
the treatment of vasculitis, and were adjudicated by the sponsor.
The major secondary efficacy end point was time from day 0 
to the first major vasculitis relapse, defined as the presence of ≥1 
major BVAS item. Efficacy assessments for clinical disease activity 
(BVAS scores) were performed at screening and on day 0, fol-
lowed by assessments at week 2, week 4, and every 4 weeks 
thereafter until study exit. Other efficacy end points included abso-
lute change in the VDI, and proportion of patients in remission 
(defined as a BVAS score of 0 and glucocorticoid dose ≤10 mg/
day) at double- blind week 48 of year 1 and double- blind week 24 
of year 2, as well as by visit.
Prohibited medications and therapies resulting in 
treatment failure. Patients who received prohibited medi-
cations or therapies at any time during the double- blind phase 
of this study were considered to have experienced a PSE from 
the day on which a treatment failure was declared. Treatment 
with the study agent was subsequently discontinued. Prohibited 
medications and therapies included the following: other immu-
nomodulatory investigational agents, rituximab, cyclophospha-
mide, other immunosuppressive agents (except for methotrexate 
for azathioprine intolerance), glucocorticoids for vasculitis (>10 
mg/day), glucocorticoids for other reasons (>20 mg/day for 
>14 days or IV glucocorticoid pulses of >125 mg), and plasma-
pheresis. Glucocorticoid doses were expressed as prednisone- 
equivalent doses.
Safety assessments. The assessment of safety included 
the monitoring of adverse events (AEs), Columbia- Suicide Severity 
Rating Scale scores (28),  and immunogenicity.
Biomarker analysis. Levels of biomarkers, including 
ANCAs (perinuclear, cytoplasmic, MPO, and PR3), serum com-
plement (C3 and C4), and serum immunoglobulins (IgA, IgM, and 
IgG), and B cell levels were measured at baseline (day 0) and at 
multiple time points thereafter. BLyS protein concentrations were 
measured on day 0 only.
Statistical analysis. Initially, this study aimed to eval-
uate the superiority of belimumab compared with placebo in 
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reducing the risk of relapse in patients with AAV who were 
in remission. However, after the reduction in sample size, the 
study became exploratory in nature. Therefore, statistical anal-
ysis was performed for the primary outcome measure only. 
Consequently, P values were not generated for other compar-
isons. Summaries presented by induction regimen relating to 
relapses, AEs, and biomarkers were not prespecified in the 
analysis plan. The final sample size was based on feasibility, 
rather than statistical considerations.
Unless otherwise stated, all analyses were performed using 
the intent- to- treat (ITT) population, defined as all randomized 
patients who received at least 1 dose of study agent (belimumab 
or placebo). Patients who discontinued placebo or belimumab 
for reasons other than a PSE were expected to continue their 
participation in the study until they experienced a PSE or com-
pleted the study (whichever came first); these patients were 
included in evaluation of the primary end point.
The primary efficacy end point, time to first PSE, was ana-
lyzed via a Cox proportional hazards model adjusted for ANCA 
type (PR3 or MPO), disease stage at induction, and induction 
regimen. Continuous variables were summarized using the 
sample number, mean ± SD values, and median (minimum to 
maximum) values. Categorical variables were summarized using 
frequency counts and percentages.
RESULTS
Study population and patient demographics. 
Overall, 164 patients with AAV were screened, and 106 were 
randomized to receive either belimumab (n = 54) or placebo 
(n = 52), of whom 105 received ≥1 dose of study agent and 
were included in the ITT population. Distribution of the patients 
is summarized in Figure 2. Patient demographics were gener-
ally similar across the treatment groups in the ITT population 
(Table 1). An imbalance was evident across the age categories: 
the proportion of elderly patients (age ≥65 years) was higher 
in the belimumab group (18 [34.0%] of 53 patients) than in the 
placebo group (8 [15.4%] of 52 patients).
Disease characteristics at baseline were generally bal-
anced across the treatment groups, except for the proportion 
of patients with relapsing disease and the duration of disease 
at baseline (Table 1). All patients included in the ITT population 
were in remission (BVAS score of 0) at baseline, and most 
had a VDI score higher than 0 (83 [79.0%] of 105 patients in 
the total population; 40 [76.9%] of 52 receiving placebo and 
43 [81.1%] of 53 receiving belimumab) (Table 1). The median 
total VDI score was 2.0 (range 0–8) for patients in the placebo 
group, and 3.0 (range 0–11) for patients in the belimumab 
group.
The median disease duration was longer in the placebo 
group compared with the belimumab group (median 833 days 
versus 482 days). More patients included in the ITT population 
had been diagnosed as having GPA (83 of 105 total, including 
41 [78.8%] of 52 in the placebo group and 42 [79.2%] of 53 in 
the belimumab group) than had been diagnosed as having MPA 
(22 of 105 total, including 11 [21.2%] of 52 in the placebo group 
and 11 [20.8%] of 53 in the belimumab group). Prior to the study, 
the majority of patients (78 [74.3%] of 105) had followed a cyclo-
phosphamide induction regimen, while 27 (25.7%) of 105 had 
received rituximab induction therapy (Table 1).
Figure 2. Distribution of patients in the intent- to- treat (ITT) population. a = not all patients who withdrew due to lack of efficacy met the 
protocol- specified event (PSE) criteria (n = 1 in the belimumab group and n = 2 in the placebo group did not meet the criteria), and in some 
cases in which patients experienced a PSE, the reason for discontinuation was reported as an adverse event rather than lack of efficacy. b 
= includes patients withdrawn from the study; patients who discontinued treatment with placebo or belimumab continued in the study until 
relapse, study withdrawal, or study completion. c = reasons for withdrawal included patient decision (n = 2), study termination (Italy) (n = 1), 
and protocol deviation (n = 1). d = reasons for withdrawal included patient decision (n = 3), study termination (Italy) (n = 1), protocol deviation 
(n = 3), and investigator decision (n = 2).
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Table 1. Demographic and baseline disease characteristics of the patients in the intent- to- treat population*
Placebo 
(n = 52)
Belimumab 10 mg/kg 
(n = 53)
Sex, no. (%) female 25 (48.1) 26 (49.1)
Race, no. (%)
White 44 (84.6) 46 (86.8)
American Indian or Alaskan Native 5 (9.6) 6 (11.3)
African American/African Heritage 1 (1.9) 1 (1.9)
Asian 2 (3.8) 0
Age, mean ± SD years 54 ± 14 56 ± 14
Age group, no. (%)
<65 years 44 (84.6) 35 (66.0)
≥65 years 8 (15.4) 18 (34.0)
Disease classification, no. (%)
GPA 41 (78.8) 42 (79.2)
MPA 11 (21.2) 11 (20.8)
BVAS total, median (min–max)† 0 (0–0) 0 (0–0)
ANCA type, no. (%)‡
PR3- ANCAs 40 (76.9) 41 (77.4)
MPO- ANCAs 12 (23.1) 12 (22.6)
ANCA positivity by immunoassay, no./total (%) 22/50 (44.0) 24/49 (49.0)
Induction regimen, no. (%)
IV cyclophosphamide 24 (46.2) 21 (39.6)
Oral cyclophosphamide 15 (28.8) 18 (34.0)
Rituximab 13 (25.0) 14 (26.4)
Current disease stage, no. (%)
Initial diagnosis 24 (46.2) 19 (35.8)
Relapsing disease 28 (53.8) 34 (64.2)
Disease duration, median (min–max) days 833 (107–5,445) 482 (3–7,538)
Previous cyclophosphamide use, no./total (%) 34/45 (75.6) 35/47 (74.5)
Cumulative lifetime exposure to 
cyclophosphamide§
No. with exposure (when known) 34 35
Median (min–max) dose, gm 11 (4–355) 10 (1–149)
Any damage on VDI items, no. (%)
Overall 40 (76.9) 43 (81.1)
Musculoskeletal 4 (7.7) 9 (17.0)
Skin/mucous membranes 2 (3.8) 1 (1.9)
Ocular 7 (13.5) 11 (20.8)
Ear, nose, and throat 24 (46.2) 28 (52.8)
Pulmonary 14 (26.9) 17 (32.1)
Cardiovascular 13 (25.0) 15 (28.3)
Peripheral vascular disease 0 1 (1.9)
Gastrointestinal 1 (1.9) 0
Renal 9 (17.3) 15 (28.3)
Neuropsychiatric 14 (26.9) 12 (22.6)
Other 8 (15.4) 7 (13.2)
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Among patients receiving maintenance therapy at baseline 
(51 in the placebo group and 52 in the belimumab group), 46 
patients (90.2%) and 47 patients (90.4%), respectively, were 
treated with azathioprine; the remaining 5 patients in each 
group received methotrexate as maintenance therapy, due to 
known tolerability issues (Table 1). In both treatment groups, the 
baseline levels of BLyS were highest in patients with rituximab- 
induced disease remission (mean ± SD BLyS levels 4.5 ± 4.00 
ng/ml in those receiving placebo versus 4.5 ± 3.40 ng/ml in 
those receiving belimumab), followed by patients with disease 
remission induced by oral cyclophosphamide (mean ± SD BLyS 
levels 1.7 ± 2.04 ng/ml in those receiving placebo versus 1.9 
± 1.70 ng/ml in those receiving belimumab), and were lowest 
in those with disease remission induced by IV cyclophospha-
mide (mean ± SD BLyS levels 1.1 ± 1.23 ng/ml in those receiving 
placebo versus 0.8 ± 0.34 ng/ml in those receiving belimumab) 
(see Supplementary Table 1, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40802/abstract). 
Efficacy. For the primary end point, time to first PSE (BVAS 
score of ≥6, presence of at least 1 predefined major BVAS item, or 
the receipt of prohibited medications for any reason), there was no 
statistically significant difference between the belimumab group 
and the placebo group (adjusted hazard ratio [HR] 1.07, 95% 
confidence interval [95% CI] 0.44–2.59; P = 0.884). Treatment 
with belimumab did not reduce the risk of a PSE in the overall 
study population (see Supplementary Figure 1, available on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40802/abstract). Overall, 21 PSEs were recorded 
during the study (11 patients in the placebo group, 10 patients in 
the belimumab group) (Table 2). The median time to first PSE was 
Table 2. Summary of relapses in the total intent- to- treat population and by induction regimen in the double- blind phase*
Placebo, no./total (%)
Belimumab 10 mg/kg
No./total (%) HR (95% CI) P
Total population
PSE 11/52 (21.2)† 10/53 (18.9)‡ 1.07 (0.44–2.59) 0.884
Vasculitis relapse 8/52 (15.4) 6/53 (11.3) 0.88 (0.29–2.65) 0.821
Cyclophosphamide induction 
regimen
PSE 7/39 (17.9) 9/39 (23.1) – –
Vasculitis relapse 5/39 (12.8) 6/39 (15.4) – –
Rituximab induction regimen
PSE 4/13 (30.8) 1/14 (7.1) – –
Vasculitis relapse 3/13 (23.1) 0 – –
* The hazard ratio (HR) with 95% confidence interval (95% CI) was calculated in the total intent- to- treat population for the risk of 
experiencing a protocol- specified event (PSE) or vasculitis relapse in the belimumab group relative to the placebo group. PSE was 
defined as a Birmingham Vasculitis Activity Score (BVAS) of ≥6 or presence of a major BVAS item or receipt of a prohibited medi-
cation for any reason, resulting in treatment failure. Vasculitis relapse was defined as a BVAS score of ≥6 or presence of a major 
BVAS item or receipt of a prohibited medication for vasculitis activity, resulting in treatment failure. 
† Two patients were not receiving placebo at the time of the PSE, of whom 1 received the final placebo dose 2 months prior to the 
PSE (not vasculitis relapse) and 1 received the final placebo dose 4 months prior to the PSE (vasculitis relapse). 
‡ One patient received the final belimumab dose 7 months prior to the PSE (vasculitis relapse). 
Placebo 
(n = 52)
Belimumab 10 mg/kg 
(n = 53)
Maintenance therapy, no./total (%)
Azathioprine 46/51 (90.2) 47/52 (90.4)
Methotrexate 5/51 (9.8) 5/52 (9.6)
Average daily prednisone dose, mean ± SD mg/day¶ 7.47 ± 2.198 7.18 ± 2.818
* GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; min = minimum; max = maximum; PR3 = proteinase 3; 
MPO = myeloperoxidase; IV = intravenous; VDI = Vasculitis Damage Index. 
† All organ system scores on the Birmingham Vasculitis Activity Score (BVAS) scale were 0 at baseline. 
‡ Historical diagnosis, i.e., all patients must have been positive for antineutrophil cytoplasmic antibodies (ANCAs) at some stage 
prior to screening. 
§ Outliers are due to previous and prolonged receipt of oral cyclophosphamide. 
¶ Glucocorticoid dose converted to prednisone- equivalent daily dose, averaged over 7 days up to, but not including, day 0. 
Table 1. (Cont’d)
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95 days (range 15–789 days) in patients receiving placebo and 
162 days (range 1–371 days) in patients receiving belimumab.
The secondary end point of time to first major relapse was 
not summarized, due to the limited number of major relapses that 
occurred during the study (none in the placebo group, 1 in the 
belimumab group). No absolute changes from baseline in the total 
VDI score were observed in the placebo group, with only minimal 
changes being seen in the belimumab group (mean ± SD change 
in VDI in year 1, week 48, 0.0 ± 0.15 in the placebo group and 
0.1 ± 0.38 in the belimumab group; in year 2, week 24, 0.0 ± 0.00 
in the placebo group and 0.2 ± 0.50 in the belimumab group). The 
majority of patients in both treatment groups were in remission 
at the year 1 week 48 and year 2 week 28 time points, as well 
as across visits during the double- blind phase (see Supplemen-
tary Table 2, available on the Arthritis & Rheumatology web site 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40802/abstract).
A total of 8 (15.4%) of 52 patients in the placebo group and 
6 (11.3%) of 53 patients in the belimumab group experienced a 
vasculitis relapse (BVAS score ≥6, presence of a predefined major 
BVAS item, or the receipt of prohibited medications for the treat-
ment of vasculitis) (Table 2). No statistically significant difference 
between the belimumab and placebo groups was identified for 
time to first vasculitis relapse (adjusted HR 0.88, 95% CI 0.29–
2.65; P = 0.821) (Figure 3A). The median time to first vasculitis 
relapse was 105.5 days (range 15–789 days) in the placebo group 
and 251.0 days (range 25–371 days) in the belimumab group.
Among patients who experienced a PSE, 3 (27.3%) of 11 in 
the placebo group and 4 (40.0%) of 10 in the belimumab group 
did not qualify as having a vasculitis relapse (see Supplementary 
Table 3, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40802/abstract).
In the placebo group, the vasculitis relapses (n = 8) were 
evenly distributed across the different induction regimens (3 of 
13 having received rituximab; 5 of 39 having received cyclophos-
phamide) and ANCA types (5 of 40 with PR3- ANCAs; 3 of 12 
with MPO- ANCAs), and occurred regardless of disease status at 
screening (3 of 24 with initial diagnosis; 5 of 28 with relapsing 
disease) (Table 2 and Figure 3B).
Figure 3. A, Kaplan- Meier plot of time to first vasculitis relapse in each treatment group. Vasculitis relapse was defined as a Birmingham 
Vasculitis Activity Score (BVAS) of ≥6, presence of a major BVAS item, or receipt of a prohibited medication for vasculitis. B, Occurrence of 
vasculitis relapse, as defined in A, in patients according to disease status at screening (initial versus relapsing disease). RTX = rituximab; CYC 
= cyclophosphamide; PR3 = proteinase 3; MPO = myeloperoxidase.
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In the belimumab group, all vasculitis relapses (n = 6) 
occurred following induction of disease remission with cyclophos-
phamide in patients with PR3- ANCAs; all but 1 patient had relaps-
ing disease at screening (1 of 19 with initial diagnosis; 5 of 34 with 
relapsing disease) (Table 2 and Figure 3B). No vasculitis relapses 
(0 of 14) occurred in the belimumab group following the induction 
of remission with rituximab, compared with 3 of 13 relapses in the 
placebo group (Table 2).
Overall, vasculitis relapses (n = 14) were reported to occur in 
11 of 81 PR3- ANCA–positive patients and in 3 of 24 MPO- ANCA–
positive patients (Figure  3B). Relapse of vasculitis occurred ir -
respective of disease state at the time of induction (4 of 43 with 
initial diagnosis; 10 of 62 with relapsing disease) (Figure 3B).
Biomarker analysis. B cells. Summaries of the data 
revealed that the induction regimen did affect B cell populations at 
baseline. Levels of B cells were at or below the lower limit of quan-
tification for patients with rituximab- induced remission. Patients 
with cyclophosphamide- induced remission also demonstrated 
notably low baseline B cell (CD19+) counts, the lowest occur-
ring following oral administration of cyclophosphamide (IV cyclo-
phosphamide, median 59.0 cells/mm3 [interquartile range (IQR) 
20.5–97.0) in the placebo group versus median 50.0 cells/mm3 
[IQR 27.0–80.0] in the belimumab group; oral cyclophosphamide, 
median 16.0 cells/mm3 [IQR 12.0–139.0] in the placebo group 
versus median 25.0 [IQR 10.0–105.0] in the belimumab group). 
Patients with cyclophosphamide- induced disease remission also 
exhibited a rapid increase in the number of circulating memory 
B cells (CD20+/CD27+) following belimumab treatment, which 
gradually returned to baseline levels, whereas no major changes 
in circulating memory B cells occurred in the placebo group (see 
Supplementary Figure 2, available on the Arthritis & Rheumatology 
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40802/
abstract), which is consistent with the pharmacodynamic effects 
of belimumab on memory B cells previously observed in patients 
with systemic lupus erythematosus.
Belimumab had no impact on the proportion of naive 
(CD20+CD27−) B cells compared with placebo following cyclo-
phosphamide induction. The number of patients with rituximab- 
induced remission who had quantifiable B cell data was low, 
with partial reconstitution occurring in only a minority of patients 
(2 of 13 in the placebo group; 4 of 14 in the belimumab group). 
 Reconstitutions did not translate into vasculitis relapses.
Serum immunoglobulins. Overall, serum IgG levels declined 
noticeably in the belimumab group compared with the placebo 
group, the latter of which showed an increase in serum IgG lev-
els, suggesting that belimumab affects antibody- secreting cells 
(see Supplementary Figure 3, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40802/abstract). The mean percentage change from base-
line in serum IgG levels at year 1, week 48 was 9.0% in the 
placebo group and −3.5% in the belimumab group. By year 
2, week 24, the mean percentage change from baseline had 
reached 20.7% in placebo patients and was −0.9% in the beli-
mumab group.
Similarly, reductions in the serum levels of both IgA and IgM 
were also observed in the belimumab group (for IgA, mean per-
centage reduction at year 1, week 48, −12.3%, and at year 2, 
week 24, −13.5%; for IgM, mean percentage reduction at year 
1, week 48, −16.9%, and at year 2, week 24, −15.8%). In con-
trast, serum IgA and IgM levels were increased in the placebo 
group (for IgA, mean percentage increase at year 1, week 48, 
7.2%, and at year 2, week 24, 6.6%; for IgM, mean percentage 
increase at year 1, week 48, 15.5%, and at year 2, week 24, 
34.8%) (see Supplementary Figures 4 and 5, available on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40802/abstract).
ANCA status. The numbers of patients found to be ANCA 
positive, as measured by immunoassay, at any time post- 
baseline were similar between the groups (32 [64.0%] of 50 
patients receiving placebo; 30 [61.2%] of 49 patients receiving 
belimumab). No trends in change in ANCA status over time were 
observed, regardless of induction regimen. Review of individual 
patient data showed no apparent trends between ANCA titers 
and AAV relapse (data not shown).
Safety. A greater proportion of patients in the belimumab 
group compared with the placebo group reported at least 1 AE 
at any time post- baseline (92.5% of patients in the belimumab 
group versus 82.7% of patients in the placebo group) (Table 3). 
The highest incidence of AEs overall was in the “infections and 
infestations” system organ class (57.7% of patients receiving 
placebo versus 56.6% of patients receiving belimumab). Infec-
tions were the most common type of AE irrespective of induc-
tion regimen. An imbalance, however, was identified among 
patients with disease remission induced with rituximab, in whom 
infections occurred to a greater extent in the belimumab group 
 compared with the placebo group. In this subset, 9 patients 
(69.2%) in the placebo group reported developing 21 infections, 
while in the belimumab group, 14 patients (100.0%) reported 
developing 50 infections (3 serious infections) (Table  3). No 
specific events were identified as driving this imbalance.
Serious AEs occurred to a similar extent in both treat-
ment groups (30.8% in the placebo group versus 34.0% in the 
belimumab group). The highest incidence of serious AEs was 
in the “infections and infestations” system organ class (7.7% 
in the placebo group versus 7.5% in the belimumab group) 
(Table 3). Overall, 7 patients (13.5%) in the placebo group and 
9 (17.0%) in the belimumab group experienced AEs leading 
to study drug discontinuation, and 1 death, attributable to 
ischemic stroke considered by the investigator to be unre-
lated to the study drug, occurred in a patient in the belimumab 
group; the patient was not receiving belimumab at the time of 
death (Table 3).
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Malignancies occurred in 4 patients (7.5%) receiving beli-
mumab; there were no malignancies in the placebo group 
(Table  3). Malignancies in the belimumab group were reported 
only among patients who received cyclophosphamide during the 
induction phase. This imbalance was predominantly driven by 3 
patients having nonmelanoma skin cancer (all occurring in elderly 
patients age ≥65 years). The other malignancies were plasma 
cell myeloma (1 patient) and anal cancer (1 patient; this patient 
also had a nonmelanoma skin cancer). Furthermore, the higher 
proportion of elderly patients receiving belimumab (18 [34.0%] 
of 53) compared with those receiving placebo (8 [15.4%] of 52) 
may have confounded the results. Overall, no clinically meaningful 
differences between treatment groups, and no trends over time, 
were identified for any malignancies.
No trends of clinical concern and no clinically meaningful 
differences between treatment groups were observed for hema-
tologic, clinical chemistry, serum IgG, or urinalysis values. None 
of the patients in the placebo group and 4 patients (7.5%) in the 
belimumab group exhibited a grade 3 IgG value (250–399 mg/dl) 
at any time post- baseline; no severe/serious infections or infec-
tions leading to treatment discontinuation were reported in these 4 
patients. No patients in either treatment group had a grade 4 IgG 
value (<250 mg/dl).
Pharmacokinetics. Belimumab levels close to the 
steady- state concentrations were reached early in the trial, and 
were maintained throughout the treatment period. The median 
peak concentration at week 2 was 297 μg/ml, which was similar 
to that at week 24 (325 μg/ml). Furthermore, the median trough 
concentrations at week 8 (90.9 μg/ml) were similar to those at 
week 48 (84.7 μg/ml).
DISCUSSION
This study investigated the safety and efficacy of belimumab, 
a monoclonal antibody that inhibits BLyS, in addition to stan-
dard of care, for the maintenance of remission in AAV following a 
standard induction regimen. This is also the first study to provide 
data related to the effect of sequential treatment with rituximab 
followed by belimumab in AAV.
Current European League Against Rheumatism and Euro-
pean Renal Association–European Dialysis and Transplant Asso-
ciation (EULAR/ERA- EDTA) recommendations for the induction of 
remission in AAV consist of treatment with a combination of glu-
cocorticoids and either cyclophosphamide or rituximab (3). Two 
randomized controlled trials (the Rituximab in ANCA- Associated 
Vasculitis and Rituximab versus Cyclophosphamide in ANCA- 
Associated Vasculitis trials) identified rituximab as being non-
inferior to cyclophosphamide; however, rituximab may be more 
effective for the treatment of relapsing disease (7,29). In addition, 
EULAR/ERA- EDTA guidelines for the maintenance of remission in 
AAV recommend treatment with azathioprine, rituximab, metho-
trexate, or mycophenolate mofetil (3). Full drug- free remission can 
be achieved in many patients with AAV; however, relapse is com-
mon and there is a need for better treatment regimens for the 
maintenance of remission (3,4,7).
As corroborated by results obtained during this study, BLyS 
levels are known to rise following therapy with rituximab (6,18,30). 
Increased BLyS levels may lead to autoreactive B cell reemer-
gence, thus promoting relapse (18). Consequently, targeting BLyS 
via the action of belimumab may help to prolong remission follow-
ing induction of remission with rituximab for AAV.
The overall rate of a PSE (21 [20.0%] of 105 patients) and 
vasculitis relapse (14 [13.3%] of 105 patients) in the current study 
was low compared with that reported in the literature (4,7). The 
majority of patients remained in remission throughout the double- 
blind phase; this may have been influenced by their ongoing 
treatment with azathioprine and glucocorticoids (31). The use of 
 prolonged treatment with azathioprine and oral glucocorticoids 
has been shown to reduce relapse rates in GPA and MPA (31). 
Belimumab plus maintenance therapy with azathioprine and oral 
glucocorticoids did not reduce the risk of a PSE or vasculitis 
relapse in patients with AAV who were in remission.
No vasculitis relapses (0 of 14) occurred in patients receiv-
ing rituximab for induction of disease remission who were sub-
sequently treated with belimumab. In contrast, 3 (23.1%) of 13 
patients in the placebo group with disease remission induced with 
rituximab did experience a vasculitis relapse. This finding in a small 
subgroup of patients warrants further investigation and is consis-
tent with data from preclinical models and case studies suggest-
ing that dual B cell–targeted immunotherapy (B cell depletion [i.e., 
rituximab] plus BLyS blockade [i.e., belimumab]) may be more 
 efficacious than either therapy prescribed alone (32–35). However, 
it should be noted that both the sample size and the number of 
events in the current study were small.
No new safety signals were identified for belimumab. Seri-
ous and nonserious infections were balanced across treatment 
arms; however, an imbalance was observed for patients with 
rituximab- induced remission. Infectious AEs in these patients 
were higher in the belimumab group compared with the placebo 
group, primarily driven by nonserious events. Furthermore, no 
differences in Ig- related toxicity were observed in this study. The 
imbalance in malignancy events observed between treatment 
groups and induction regimens may have been related to the 
greater proportion of elderly patients receiving belimumab com-
pared with those receiving placebo.
Several limitations related to the study should be con-
sidered. First, a number of recruitment difficulties, primarily 
relating to the advancement of standard of care treatment 
options, including the licensing of rituximab for the treatment 
of AAV, led to truncation of the intended sample size from 
~300 to ~100 patients. Furthermore, evidence for the supe-
rior efficacy of rituximab as a therapy for the maintenance of 
remission, compared with azathioprine, was communicated 
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after the study started (4). Consequently, the study consists 
of a small sample size with reduced power for the primary 
outcome analysis; caution is therefore required in interpreta-
tion of the results. Future studies regarding the maintenance 
of remission in AAV with belimumab as monotherapy may 
increase the ability of the trial to detect potential treatment 
benefit.
In conclusion, the addition of belimumab to a regimen 
of azathioprine with low- dose glucocorticoids for the mainte-
nance of remission in AAV did not reduce the risk of a PSE or 
vasculitis relapse. However, patients with rituximab- induced 
remission who were subsequently treated with belimumab 
exhibited no vasculitis relapses. This observation warrants fur-
ther investigation.
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